Relative abundance of the Prevotella genus within the human gut microbiota of elderly volunteers determines the inter-individual responses to dietary supplementation with wheat bran arabinoxylan-oligosaccharides. by Chung, Wing Sun Faith et al.
RESEARCH ARTICLE Open Access
Relative abundance of the Prevotella genus
within the human gut microbiota of elderly
volunteers determines the inter-individual
responses to dietary supplementation with
wheat bran arabinoxylan-oligosaccharides
Wing Sun Faith Chung1, Alan W. Walker1, Douwina Bosscher2, Vicenta Garcia-Campayo3, Josef Wagner4,
Julian Parkhill5, Sylvia H. Duncan1* and Harry J. Flint1
Abstract
Background: The human colon is colonised by a dense microbial community whose species composition and
metabolism are linked to health and disease. The main energy sources for colonic bacteria are dietary polysaccharides
and oligosaccharides. These play a major role in modulating gut microbial composition and metabolism, which in turn
can impact on health outcomes.
Results: We investigated the influence of wheat bran arabinoxylan oligosaccharides (AXOS) and maltodextrin
supplements in modulating the composition of the colonic microbiota and metabolites in healthy adults over the age of
60. Male and female volunteers, (n = 21, mean BMI 25.2 ± 0.7 kg/m2) participated in the double-blind, cross over
supplement study. Faecal samples were collected for analysis of microbiota, short chain fatty acids levels and calprotectin.
Blood samples were collected to measure glucose, cholesterol and triglycerides levels. There was no change in these
markers nor in calprotectin levels in response to the supplements. Both supplements were well-tolerated by the
volunteers. Microbiota analysis across the whole volunteer cohort revealed a significant increase in the proportional
abundance of faecal Bifidobacterium species (P≤ 0.01) in response to AXOS, but not maltodextrin, supplementation. There
was considerable inter-individual variation in the other bacterial taxa that responded, with a clear stratification of
volunteers as either Prevotella-plus (n = 8; > 0.1% proportional abundance) or Prevotella-minus (n = 13; ≤0.1% proportional
abundance) subjects founded on baseline sample profiles. There was a significant increase in the proportional abundance
of both faecal Bifidobacterium (P≤ 0.01) and Prevotella species (P≤ 0.01) in Prevotella-plus volunteers during AXOS
supplementation, while Prevotella and Bacteroides relative abundances showed an inverse relationship. Proportional
abundance of 26 OTUs, including bifidobacteria and Anaerostipes hadrus, differed significantly between baseline samples
of Prevotella-plus compared to Prevotella-minus individuals.
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Conclusions: The wheat bran AXOS supplementation was bifidogenic and resulted in changes in human gut microbiota
composition that depended on the initial microbiota profile, specifically the presence or absence of Prevotella spp. as a
major component of the microbiota. Our data therefore suggest that initial profiling of individuals through gut microbiota
analysis should be considered important when contemplating nutritional interventions that rely on prebiotics.
Trial registration: Clinical trial registration number: NCT02693782. Registered 29 February 2016 - Retrospectively
registered, https://clinicaltrials.gov/ct2/show/NCT02693782?term=NCT02693782&rank=1
Keywords: Gut microbiota, Diversity, Bacteroides, Prevotella, Bifidobacteria, Wheatbran extract, Arabinoxylan
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Background
The human large intestine is colonised by a dense micro-
bial community, comprised of a large number of different
species mainly belonging to the Bacteroidetes, Firmicutes
and Actinobacteria phyla [1], and microbial composition
can have a major impact on health outcomes [2]. The
composition of the gut microbiota is considered to be
driven primarily by diet, geographical location and age [3,
4]. Actinobacteria typically account for around 5% of the
microbiota in faecal samples from healthy adults and Bifi-
dobacterium is one of the most abundant constituent gen-
era in this phylum [5]. There has been particular interest
in bifidobacteria because of their use as probiotics and as
targets for prebiotics [6]. The abundance of bifidobacteria
is diminished in the elderly [6, 7] and low abundance of
bifidobacteria is also associated with health disorders
including inflammatory bowel disease [8].
The species composition of the colonic microbiota is also
likely to be driven by dietary macronutrients, in particular
non-digestible carbohydrates derived from plant fibre [9,
10]. Among the Bacteroidetes phylum, the two most preva-
lent genera in the human colon are generally Bacteroides
and Prevotella. It has been proposed that high dietary fibre
intake is associated with a Prevotella dominated microbiota
[11], whereas high intake of fat and protein is associated
with a Bacteroides dominated microbiota, based on a survey
of 98 US adults [11–13]. Indeed, microbiota profiling stud-
ies carried out in agrarian, and high-fibre consuming, popu-
lations around the World have consistently reported that
the Prevotella genus is more dominant than in urbanised
societies typically consuming lower fibre diets, where Bac-
teroides typically appear to be more predominant [11, 14].
Human studies allow us to gain unique information on
the dynamics of the gut microbial community and have
revealed that changes in diet-responsive species can
occur rapidly, often within a few days of the dietary in-
terventions, with concomitant alterations in microbial
metabolite formation [15–18]. There is a pressing need
to identify the types of bacterial taxa that can be pro-
moted by specific dietary components, and in turn how
dietary-induced shifts in microbiota composition and ac-
tivities might impact on the host [2, 4, 19, 20].
It has been demonstrated that arabinoxylan oligosac-
charides (AXOS) have beneficial properties across differ-
ent age groups including promotion of faecal
bifidobacteria abundance and overall short chain fatty
acid levels [21–26]. AXOS are short-oligosaccharides ob-
tained from the hydrolysis of arabinoxylans that are
composed of a linear backbone of β-1,4-linked D-
xylopyranosyl residues (xylose), some of which are
substituted with α-L-arabinofuranosyl residues (arabin-
ose) that can be ester-linked with ferulic acid [27].
Here we investigated the impact of dietary supplementa-
tion with wheat bran-derived AXOS or maltodextrin on
gut microbiota composition and metabolites in 21 free liv-
ing, elderly volunteers. AXOS, but not maltodextrin, sup-
plementation generally increased bifidobacteria
proportional abundance, but faecal microbiota responses
to AXOS differed significantly between individuals who
were Prevotella-positive (Prevotella-plus group) and those
who were Prevotella-negative (Prevotella-minus group) at
baseline. The eight volunteers presenting as Prevotella-
plus showed a significant increase in faecal total short
chain fatty acids and propionate during the AXOS supple-
mentation. These findings have important consequences
for our understanding of inter-individual responses to a
wheat bran AXOS dietary supplement and are likely to
have important consequences for health.
Results
Demographics and metadata for human volunteers
Free living male and female (BMI 20–32 kg/m2), elderly
volunteers that met the inclusion criteria for the study
(see Materials and Methods) were given either AXOS
extracted from wheat bran or maltodextrin supplements
in a randomised, cross-over, double-blinded manner.
Maltodextrin was chosen as a comparator and the two
supplementation periods had a duration of ten days each
and were separated by washout periods of 5 days each.
Faecal samples were collected every 5 ± 1 days. Blood
collection and blood pressure measurements were per-
formed at the beginning and the end of each supplemen-
tation period (Fig. 1).
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Supplements of both wheat bran AXOS (Brana Vita®
21,760) and maltodextrin were provided in sachets con-
taining 5 g of the powdered supplement and consumed
three times per day to give to total of 15 g/d (97% dry
matter). The two supplements were delivered in a
double-blinded manner. Compliance was determined by
weigh back of residual powders in the used sachets. The
compliance for the supplements in the AXOS and
maltodextrin periods were 96 and 95.9% respectively.
Male and female volunteers aged 60 years and above, with
a body mass index (BMI) between 20 and 32 kg/m2 (which
is within the normal to slightly obese BMI range) were re-
cruited locally (Aberdeen, UK). Of the 26 volunteers who
attended for screening five volunteers did not participate
further in the study due to unspecified personal reasons
(volunteers 007, 012, 015, 016, and 017). Twenty-one vol-
unteers (average age of 69.7 years and an average BMI of
25.2 kg/m2) completed the study (eight males and thirteen
females) (Table 1). The volunteers were randomised into
two groups. Group 1 (n = 8) received the maltodextrin sup-
plement in the first period then AXOS supplement in the
second period, whereas group 2 (n = 13) received the AXOS
supplement in the first period then the maltodextrin sup-
plement in the second period. All twenty-one volunteers
who completed the study provided a complete set of seven
faecal samples, except for volunteer 008 (Additional file 1:
Table S1) who provided five faecal samples (samples lack-
ing for visits 1 and 5). All volunteers, with the exception of
volunteer 022, provided blood samples.
Habitual dietary intakes were recorded twice (beginning
and end) within the study period using food frequency
questionnaires (Fig. 1). The mean macronutrient content
of the volunteers’ daily diet comprised 61.8% carbohydrate
(which included sugars), 17.9% protein and 17.3% fat (in
addition to 3% minerals and vitamins) (n = 42 representing
two measurements per volunteer). Habitual dietary fibre
intake per volunteer was variable and ranged from 11 to
39 g/day, with an average of 21 g/day across all volunteers
(Fig. 2).
Gastrointestinal tolerance
Gastrointestinal tolerance was recorded daily by the vol-
unteers (n = 21) throughout the study and the symptoms
(as defined in the Materials and Methods) were scored be-
tween 0 and 3 for no more, slightly more, noticeably more,
or considerably more symptoms than usual. There were
no reported ill-effects for the two treatment periods and
all score changes were less than 1, indicating very mild to
no effect, with excellent compliance for the supplements
in the AXOS and maltodextrin periods (data not shown).
Stool appearance was also recorded daily and the majority
of the samples from all three periods (washout control
period, AXOS supplementation and maltodextrin supple-
mentation) were reported as normal.
Effect of arabinoxylan-oligosaccharide (AXOS) on the
human gut microbial communities
The intestinal bacterial communities were analysed
using Illumina MiSeq sequencing of PCR amplified (V1-
V2 region only) 16S rRNA genes from faecal samples,
including samples from the initial washout, intermediate
and end time points from the first supplement period,
the middle washout, intermediate and end time points
from the second period and the final washout. A total of
152 samples were analysed overall, resulting in a total of
573,488 sequences (Additional file 2: Table S2).
Fig. 1 Schematic of the cross-over, randomised, double-blinded design of the human dietary supplementation study, incorporating the addition
of Wheat Bran Extract arabinoxylan oligosaccharide (AXOS) and maltodextrin. Control periods, when volunteers were not receiving supplements
(5 days each) were included before, in between, and after the supplementation periods (10 days per supplement). Study visits and sample
collection days are indicated. Faecal samples were collected at each visit. Blood samples and blood pressure measurements were collected at the
start and end of each supplementation period. Food frequency questionnaires were completed at the beginning and end of the study
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As is typically observed with human gut microbiota
studies, there was a large degree of inter-individual vari-
ation in response to dietary supplementation, and the
most abundant phyla were Firmicutes, Bacteroidetes, Acti-
nobacteria and Proteobacteria [4, 28]. However, across the
entire cohort of volunteers there was an increase in pro-
portional abundance of Actinobacteria during the AXOS
supplementation period compared to both the maltodex-
trin supplementation (Metastats, p < 0.001) and washout
control periods (p < 0.001). The mean proportional abun-
dance of Bacteroidetes was also significantly higher during
AXOS supplementation (p < 0.001) with a concomitant
proportional decrease in Firmicutes (p < 0.001; Fig. 3a).
This observed increase in the proportional abundance
of Actinobacteria was mainly driven by an increase at
the family level of Bifidobacteriaceae when compared to
the washout control and maltodextrin supplementation
periods (p < 0.05; Fig. 3b).
Stratification of volunteers based on faecal microbiota
composition
Further inspection of the microbiota data indicated a
distinct split in the types of bacteria that responded to
the AXOS supplementation, which depended fundamen-
tally on the baseline microbiota composition of the vol-
unteers. These data revealed a subgroup of eight
volunteers who were Prevotella-positive (plus) (volun-
teers 1, 4, 6, 8, 9, 14, 22 and 24), as their baseline sam-
ples showed > 0.1% proportional abundance of total
Prevotellaceae (range 2.7–28.4%) whilst the remaining
13 volunteers (2, 3, 5, 10, 11, 13, 18, 19, 20, 21, 23, 25
and 26) had low (cut-off set at ≤0.1%) or no detectable
Prevotella spp. at their baseline sample. The propor-
tional abundance of Bacteroides spp. was significantly
higher in the Prevotella-minus than in the Prevotella-
plus group (OTU0003 Bacteroides uniformis p = 0.001
and OTU0020 Bacteroides cellulosilyticus p = 0.001)
(Additional file 3: Table S3). Overall, 26 of the most
abundant operational taxonomic units (OTUs) (those
comprising > 0.5% of sequences in baseline samples) dif-
fered significantly between the Prevotella-plus and Pre-
votella-minus groups (Additional file 3: Table S3).
Analysis of the microbiota in the Prevotella-plus group
at the family level showed a significant increase in Pre-
votellaceae proportional abundance during the AXOS
supplementation period compared to both the washout
Table 1 Summary of the completed volunteer demographics (n = 21), showing gender, age, height, weight and BMI. Values are
shown as mean ± SEM and range
MEAN ± SEM (Range)
Age (yrs) Height (m) Weight (kg) BMI (kg/m2)
Males (n = 8) 68.3 ± 1.74 (61–75) 1.7 ± 0.02 (1.608–1.773) 75.63 ± 3.76 (57.35–87.85) 26.14 ± 1.01 (22.18–30.18)
Females (n = 13) 67.31 ± 1.26 (60–74) 1.61 ± 0.01 (1.493–1.693) 63.61 ± 2.66 (48.9–81.9) 24.6 ± 0.95 (18.98–31.25)
All (n = 21) 67.67 ± 1 (60–75) 1.64 ± 0.02 (1.493–1.773) 68.19 ± 2.49 (48.9–87.85) 25.18 ± 0.71 (18.98–31.25)
Fig. 2 Habitual dietary fibre intake from different dietary sources per volunteer from data collected via food frequency questionnaires. The total intake of
dietary fibre ranged from 10.6 to 38.5 g/day with an average of 20.9 g/day across the volunteers. Currently, the recommended average fibre intake for
adults in the UK is 30 g/day. (https://www.gov.uk/government/publications/sacn-carbohydrates-and-health-report). # Indicates Prevotella-plus individuals
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and maltodextrin periods (LEfSe, p = 0.002, validated with
Wilcoxon-ranked test p = 0.014) (Additional file 4: Table
S4) and a decrease in Bacteroidaceae proportional abun-
dance (LEfSe, p = 0.005, not significant with Wilcoxon-
ranked test) (Fig. 4a-d) compared to baseline. The propor-
tional abundance of both the Bifidobacteriaceae family
and Bifidobacterium genus were significantly higher dur-
ing the AXOS period compared to the maltodextrin and
control (baseline) periods for both the Prevotella-plus and
Prevotella-minus group of volunteers (LEfSe, p < 0.0001)
(Fig. 4b) (Fig. 4e). In contrast to AXOS, the maltodextrin
supplementation period was associated with increased
proportional abundance of the Bacteroidaceae family, and
Bacteroides genus, in the Prevotella-plus group of volun-
teers only (LEfSe, p = 0.005). No genera or families were
associated with maltodextrin supplementation in the Pre-
votella-minus group of volunteers using LEfSe (Additional
file 4: Table S4). There was a weak, non-significant correl-
ation between fibre intake and Prevotella proportional
abundance in the Prevotella-plus group (R2 = 0.503, p =
0.074) (Fig. 5) but the mean fibre intake for the Prevotella-
plus group was significantly higher (25.0 g/d) than for the
Prevotella-minus group (19.1 g/d) (p = 0.025). Consider-
able inter-individual variation was observed between vol-
unteers at the phylum and family level (Additional file 5:
Fig. S1).
Seven out of the eight Prevotella-plus volunteers pos-
sessed a high proportional abundance of Prevotella copri
(OTU0002, OTU0012 and OTU0075), which cumula-
tively accounted for up to around 40% of the sequence
reads when certain volunteers were on the AXOS
supplements, with the presence of multiple Prevotella
OTUs in most of these volunteers. One of the volunteers
(volunteer number 1) however had a high proportional
abundance of P. ruminicola (OTU0022) rather than P.
copri. (Fig. 6a). Of the top 100 out of 2563 OTUs de-
fined using a cut off of 97% sequence similarity (each
representing > 0.22% of the total number of sequences),
the most abundant OTUs were identified as P. copri
(OTU0002) and Prevotella spp. (OTU0012) in the Prevo-
tella-plus group (Additional file 6: Table S5A). Bacter-
oides vulgatus (OTU0001) and Bacteroides uniformis
(OTU0003) were most prevalent in the Prevotella-minus
group of volunteers (Additional file 6: Table S5B). Over-
all, the proportional abundance of Prevotella spp. was
negatively correlated with that of Bacteroides spp. across
the eight Prevotella-plus group responders, but the anti-
correlation only reached significance during the AXOS
supplementation period (R2 = 0.657, p = 0.015) (Fig. 6b).
Bifidobacterium longum was detected in all baseline sam-
ples across the volunteers, with the exception of volunteer
24 (Fig. 4e and Additional file 6: Table S5) and B. longum
(OTU0011) was found to be the most proportionally abun-
dant species/OTU, followed by Bifidobacterium adolescen-
tis (OTU0014). Moreover, when comparing the washout
periods, two Bifidobacterium OTUs were more prevalent in
the Prevotella-minus group, namely B. longum (OTU0011,
p = 0.001) and B. adolescentis (OTU0014, p = 0.012). This
may also help to explain the higher proportional abundance
of Anaerostipes hadrus (OTU0015, p = 0.0001), a lactate
utilising-butyrate producing species present in greater pro-
portional abundance in the Prevotella-minus group
Fig. 3 Mean proportional abundance of bacteria at (a) the phylum and (b) the family level during the maltodextrin, AXOS and control (washout)
periods determined by Illumina sequencing. (* = For panel A, p < 0.001; for panel B, p < 0.05)
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(Additional file 3: Table S3), as bifidobacteria generate lac-
tate as a fermentation end product.
Bacterial community diversity indices
Bacterial community α-diversity was measured using the
Shannon index. Across the entire cohort of volunteers
there was no significant change in diversity during the
AXOS supplementation period when compared to the
maltodextrin and washout periods. Microbial community
analysis of samples from the maltodextrin supplementa-
tion period showed similar diversity with the washout
period (Additional file 7: Fig. S2). When looking at the
data stratified by Prevotellaceae presence at baseline the
Shannon diversity index was significantly lower during the
AXOS supplementation period (compared with washout
period) for the Prevotella-plus group of volunteers (Wil-
coxon p < 0.04).
Faecal short chain fatty acid levels
Faecal short chain fatty acids were measured for all volun-
teers (n = 21) at the beginning of the study (control), mid-
dle (intermediate supplement) and end (last supplement)
Fig. 4 Mean proportional bacterial abundance changes at (a) the family level for the Prevotella-plus group (Prevotellaceae p = 0.002, Bifidobacteriaceae
p = 0.0002, Bacteroidaceae p = 0.004) and (b) Prevotella-minus group (Bifidobacteriaceae p < 0.0001) during maltodextrin, AXOS supplementation and
washout periods. Mean proportional abundance of (c) Prevotella spp. (Prevotella-plus group genus level, increased during AXOS supplementation p =
0.002), (d) Bacteroides spp. (Prevotella-plus group genus level, decreased during AXOS supplementation p = 0.004), and (e) Bifidobacterium spp.
(Prevotella-plus group genus level, increased during AXOS supplementation p = 0.0001, Prevotella-minus group, AXOS p < 0.0001) during the
maltodextrin, AXOS and washout periods. *p≤ 0.01, significance from LEfSe analysis comparing across all three supplement periods
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of each of the two supplementation periods, and also at
the end of the second supplement period after a washout
period (washout visit 7), which gave a total of seven mea-
surements per volunteer. There was considerable inter-
individual variation in SCFA concentrations, with the total
SCFA levels in the washout period ranging from 23.2 to
94.8mM (Additional file 8: Fig. S3).
Mean total SCFA concentrations for the 21 volunteers
were increased by the AXOS supplement compared to the
washout period (p = 0.002) and the maltodextrin supple-
ment (p = 0.003). There was no significant change in pro-
portional distribution of acetate, propionate or butyrate
among total SCFA with either the dietary intervention, or
with Prevotella-plus/minus status (Additional file 9: Fig. S4)
There was no significant association between propionate
percentage of total SCFA and the proportional abundance
of Prevotella and Bacteroides spp. (Fig. 7a and b). However,
within the Prevotella-plus group, the relative abundance of
Prevotella spp. showed a significant positive correlation
with both propionate (p < 0.0001) and total SCFA (p <
0.0001) concentrations (Fig. 7c and d respectively).
Faecal calprotectin levels
Faecal calprotectin levels were measured in the faecal
samples from the washout, maltodextrin and AXOS sup-
plementation periods and there were no differences
between the three periods across all the volunteers (p =
0.448). There were no significant differences in calpro-
tectin levels between the AXOS and maltodextrin pe-
riods, or between the Prevotella-plus/minus groups of
volunteers. (Additional file 10: Fig. S5).
Serum cholesterol, glucose, HDL, LDL, triglyceride levels
and blood pressure measurements
Blood serum parameters, glucose, HDL, LDL and triglyc-
erides, were measured at the beginning and end of each
supplementation period (n = 20, as one volunteer did not
provide blood samples). There were no significant differ-
ences between the four periods (first supplement wash-
out, second supplement washout, maltodextrin and
AXOS supplements) in either the levels of cholesterol,
glucose, HDL cholesterol, LDL cholesterol, triglyceride
and the LDL-HDL ratios for the Prevotella-plus and Pre-
votella-minus groups (Additional file 11: Fig. S6).
Discussion
This study investigated the impact of wheat bran AXOS
on faecal microbiota and short chain fatty acid profiles
in a human supplementation study. Here, the compos-
ition of the microbial communities was influenced by
the nature of the dietary supplements. Maltodextrin re-
sulted in relatively modest changes in gut microbial
Fig. 5 Correlation of habitual fibre intake and Prevotella proportional abundance from first washout sample (baseline) in the Prevotella-plus group
of volunteers (R2 = 0.503, p = 0.07). One volunteer in the Prevotella-plus group (volunteer 8) did not provide a first washout sample and therefore
was not included in this figure
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composition in comparison with AXOS. Furthermore, it
did not result in an increase in faecal calprotectin levels al-
though other studies, mostly conducted in rodents, have re-
ported that maltodextrin supplements may promote gut
inflammation [29]. During the AXOS supplementation
period the changes occurred rapidly, within the first sam-
pling point (at day 5), as has been reported in other studies
[1, 2, 15, 16, 30]. Bifidobacterium species were significantly
stimulated in the AXOS supplement period, in agreement
with previous studies [27, 31, 32]. B. longum was identified
as the predominant species within the bifidobacteria and
was significantly more proportionally abundant during the
AXOS supplementation period compared to baseline (p =
0.022) and maltodextrin supplementation periods (p =
0.015) for all volunteers. This may be important as
bifidobacteria are generally considered beneficial to health
and their proportional abundance is often diminished in
certain disease states and in the elderly, particularly the frail
elderly [33]. As such, AXOS may be considered a viable
prebiotic option in elderly cohorts, where the aim is to pro-
mote the growth of bifidobacteria. It is important to note,
however, that bifidobacteria are not the only bacterial group
to be promoted by this substrate and conclusive evidence
on their benefits for health is still needed.
Crucially, in this study we show that the microbiota
responses to AXOS supplementation depended on the
initial composition of the microbiota (Prevotella-plus or
Prevotella-minus groupings). There was large inter-
individual variation in the composition of the gut micro-
biota in the baseline samples with eight out of the 21
Fig. 6 a Changes in the proportional abundance of selected Bacteroides spp. and Prevotella spp. operational taxonomic units (OTUs) per volunteer during
the maltodextrin supplementation periods for the Prevotella-plus and Prevotella-minus groups and M=maltodextrin, A = AXOS supplementation periods,
W =washout period. b Correlation between Bacteroides spp. and Prevotella spp. proportional abundance, for the Prevotella-plus group, during the initial
washout period (R2 = 0.027, p= 0.698), AXOS supplement period (R2 = 0.657, p= 0.015) and maltodextrin supplementation period (R2 = 0.376, p= 0.106)
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volunteers exhibiting a Prevotella dominant microbiota
whilst the other volunteers showed a Bacteroides dom-
inant population. An anti-correlation between Prevo-
tella and Bacteroides spp. has been reported previously,
with some authors referring to these as ‘enterotypes’
[12, 34–36]. Since it is not yet established that these
gut microbial communities conform to a common
microbiota composition we prefer to avoid applying
the term ‘enterotype’ and this view is strongly sup-
ported by an extensive recent analysis of metagenome
data [37].
The increase in Prevotella proportional abundance
during the AXOS supplementation period suggests a
possible dietary cause for the Prevotella-plus and -minus
microbiota profiles [36]. Previously, it was suggested that
Bacteroides spp. predominance was associated with ani-
mal fat and protein based diets and Prevotella spp. were
associated with diets containing higher amounts of diet-
ary fibre [11, 12, 38]. Our results suggest that AXOS
may be one fibre type that favours the growth of Prevo-
tella within the human gut.
It has also been shown that Prevotella-predominant fae-
cal microbiota profiles tend to be associated with rapid
gut transit as assessed by Bristol stool scores [39]. In the
current study habitual dietary fibre intake was slightly
higher overall, but not significantly, in the Prevotella-plus
than in the Prevotella-minus individuals and the percent-
ages of Prevotella correlated with total SCFA concentra-
tions in faeces for the washout samples. Faecal SCFA
concentrations have been shown to increase with the rate
of gut transit in humans, and gut transit is promoted by
fibre intake [39]. On the other hand, the habitual fibre in-
takes of Prevotella-minus and Prevotella-plus individuals
showed considerable overlap in our study and there was
no significant correlation overall between fibre intake and
the relative abundance of Prevotella. This might reflect in-
dividual differences in gut transit that are independent of
fibre intake, or other unknown host factors. Alternatively,
it may be that there is some form of mutual antagonism
between the major Bacteroides and Prevotella species
within the human gut microbiota that tends to preclude
their coexistence. Prevotella spp. have also been found to
Fig. 7 Correlation between the proportional abundance of Bacteroides and Prevotella spp. and propionate (%) during washout, maltodextrin and
AXOS supplement periods for the (a) Prevotella-plus group and (b) Prevotella-minus group, (c) the correlation between proportional abundance of
Prevotella spp. % and propionate concentration (mM) (p < 0.0001) and (d) the correlation between proportional abundance of Prevotella spp. %
and total SCFA concentration (mM) (p < 0.0001)
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predominate over Bacteroides spp. in the microbiota of
rural communities including hunter gatherers [11, 40].
Overall, these data suggest that Prevotella outcom-
peted Bacteroides for the supplementary AXOS in the
Prevotella-plus group of volunteers, since Bacteroides
proportional abundance decreased significantly with
AXOS. Interestingly, bifidobacteria were significantly
stimulated by AXOS in both Prevotella-plus and Prevo-
tella-minus volunteers. This suggests that both Prevo-
tella and certain bifidobacteria (notably B. longum) were
able to benefit from the presence of AXOS. On the other
hand, bifidobacteria were initially less proportionally
abundant in Prevotella-plus than in the Prevotella-minus
volunteers, and their AXOS-stimulated proportional
abundances correspondingly lower.
In this study the response to AXOS supplements was
dependent on the initial composition of the volunteers’
microbiota when stratified into Prevotella-plus and -minus
groups. The health consequences of increasing the domin-
ance of Prevotella spp. are still largely unknown [41]. Evi-
dence is mixed and may be context dependent. For
example, P. copri has been reported to be associated with
several inflammatory conditions including the onset of
rheumatoid arthritis [42] and ankylosing spondylitis [43]. In
contrast, a microbiota that is dominated by Prevotella spp.
is associated with increased weight loss on long term diets
[44] and, separately, Gu et al. [45] reported that diabetic
patients dominated by Prevotella exhibited greater
improvements in metabolic parameters following acarbose
treatment compared to those dominated by Bacteroides.
Furthermore, in children in low to middle income coun-
tries, Prevotella species are anti-correlated with diarrhoeal
disease, indicating that they may have a protective role [38].
Given the limited number of cultured isolates and refer-
ence genomes available for P. copri there is relatively little
genotypic and phenotypic information available on this
bacterium [46]. Recent whole shotgun metagenomics-
based work has, however, indicated that P. copri is more
diverse than considered previously, and is comprised of
four distinct clades [47]. This inherent diversity may be an
important driver of the opposing health impacts associ-
ated with P. copri and is worthy of further investigation.
Interestingly, in the current study there were individuals
that harboured multiple distinct Prevotella OTUs, indicat-
ing that these clades may not be mutually exclusive. How-
ever, given the comparatively lower resolution of partial
16S rRNA gene sequences, whole shotgun metagenomics-
based studies, and attempts to culture and genome se-
quence key isolates, could provide more detailed informa-
tion regarding whether specific sub-types of Prevotella
species might respond to AXOS-based dietary interven-
tions, and their potential subsequent impacts on health.
We also found that the Prevotella-plus and Prevotella-
minus groups differ in the proportional abundance of
many other bacterial OTUs that have potential health
consequences. In particular, bifidobacteria were less pro-
portionally abundant both before and after AXOS-
stimulation in the Prevotella-plus group. Taken together,
these conflicting associations suggest that improved pre-
biotic interventions may need to be stratified in future,
to ensure optimal promotion of target organisms, and to
avoid promoting the growth of bacterial groups that may
be associated with ill-health. In the future, microbiota
profiling is therefore likely to become an important tool
that will be needed for personalised nutritional [48] and
medical advice [42, 45].
Conclusions
This study revealed rapid changes in faecal microbiota
composition in response to consuming wheat bran AXOS
supplements. In particular, Bifidobacterium species which
are commonly associated with health, were significantly
stimulated by AXOS, as reported previously [49–51]. Im-
portantly, the results also revealed considerable inter-
individual variation in the composition of the volunteer’s
faecal microbiota. Approximately 40% of the volunteers
supported a Prevotella dominant microbiota compared to
a Bacteroides dominant profile, and in these individuals
the AXOS supplements favoured proliferation of the Pre-
votella genus, which correlated with a significant increase
in total faecal SCFA levels. Given the inter-individual vari-
ation in responses, microbiota profiling should therefore
be considered when testing the efficacy of both existing
and novel prebiotics in the future.
Methods
Volunteer recruitment and medical health screening
A study brochure, radio advertisement and notice boards
were used to promote the study. Inclusion criteria for the
study were as follows: both male and female volunteers
were recruited to the study if they were aged 60 years and
above, with a body mass index (BMI) 20–32 kg/m2 which is
within the normal to slightly obese BMI range. The volun-
teers were invited for medical screening with a GP using
medical health screening questionnaires. Exclusion criteria
were as follows: Intolerance to fructose or any of the ingre-
dients in the prebiotic mix, on prescription antibiotics
within the past 3months, bowel disorders, vegetarian or
vegan, eating disorders and food intolerances, wheat and
gluten allergy, coeliac disease, alcohol and/or other sub-
stance abuse, regular intake of prebiotic or probiotic sup-
plements, smoking, psychiatric disorders resulting in
perceived inability to give informed consent, lipid/choles-
terol lowering medication (Additional file 1: Table S1A).
Human dietary supplements
Participants consumed their habitual diet throughout
the controlled, cross-over, randomised, double-blinded
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study. Test products were packaged in similar wrap-
pings. The AXOS and maltodextrin supplements were
taken orally in 5 g amounts, three times daily with meals.
The study was approved by the Ethics Committee of the
Rowett Institute, University of Aberdeen (study number
HSMC/15/004). This trial was registered at clinicaltrials.
gov no. NCT02693782.
Eligible volunteers (metadata provided in Additional
file 1: Table S1) were randomised to receive either
AXOS or maltodextrin as their first supplement. The
wheat bran extract provided by Cargill Inc. was com-
prised of arabinoxylan oligosaccharides (AXOS; 71%)
with an average degree of polymerisation (DP) of 5 and
the β-glucan content was 15%. The maltodextrin (C Dry
MD 01910) contained 95% carbohydrate, of which 4%
were sugars with a dextrose equivalent (DE) of 12–16.
Following the initial 5 days of maintenance diet (their
habitual diet), the volunteers provided faecal samples
and blood samples for analysis at regular intervals (Fig.
1). The study ended with a 5-day washout period.
Food frequency (FFQ) and gastrointestinal tolerance
questionnaires
Volunteers were requested to complete semi-
quantitative and validated [52] Food Frequency Ques-
tionnaires (FFQ) at the start and end of the study (Scot-
tish Collaborative Group version 6.6, University of
Aberdeen, Aberdeen, UK) (Fig. 1). Food consumption
was recorded as measures per day and then number of
days per week. Nutrient content of the calculated daily
consumption of the food were derived by entering the
McCance & Widdowsons’ food code and weight per day
into nutrient analysis package Windiets [53].
Gastrointestinal tolerance
Gastrointestinal tolerance was determined using a daily
questionnaire, with volunteers requested to record any
gastrointestinal changes. Bowel movements were re-
corded as number of movements between 0 and 3 or
greater than 3. Stool appearance was recorded as nor-
mal, hard or watery.
Faecal sample collection, preparation and storage
Volunteers were provided with faecal sample collection
kits that contained a leak proof bag. The samples were
processed within 5 h of collection by manually mixing
the sample for 1–2 min to give an even consistency. Ali-
quots (5 g) of the mixed faecal samples were placed into
Dispomix tubes (MACS Miltenyl Biotec), with 5 ml of
PBS buffer containing 30% glycerol. The Dispomix tubes
were then homogenised by mixing at 3900 rpm, for 5 s
forward and reverse over 65 s. The homogenised samples
were aliquoted into lysing matrix E tubes in 0.45 ml vol-
umes prior to DNA extraction using the FastDNA Spin
kit for Soil (MP Biomedicals, Illkirch, France). For SCFA
analysis, 1.5 ml sterile water was added to 0.5 g of each
sample and then vortex mixed for 2 to 3 mins until the
sample was homogenised. These were then centrifuged
at 1500 g for 10 mins to pellet debris, and 1 ml of super-
natant was removed and stored at -20 °C for subsequent
SCFA analysis.
DNA extractions from human faecal samples
DNA was extracted immediately from Dispomix prepared
samples using the FastDNA Spin kit (MP Biomedicals, Ill-
kirch, France). For each sample collected, 450 μl was placed
in lysing matrix E tubes and 978 μl of sodium phosphate
buffer and 122 μl MT buffer were added to each tube,
which was processed following manufacturer’s instructions.
The DNA was eluted in 50 μL FastPrep elution buffer.
PCR amplification and Illumina MiSeq sequencing
The extracted DNA was used as a template for PCR amplifi-
cation of the V1-V2 region of bacterial 16S rRNA genes using
the barcoded fusion primers MiSeq-27F (5′-AATGATAC
GGCGACCACCGAGATCTACACTATGGTAATTCCAG
MGTTYGATYMTGGCTCAG-3′) and MiSeq-338R (5′-
CAAGCAGAAGACGGCATACGAGAT-barcode-AGTCA
GTCAGAAGCTGCCTCCCGTAGGAGT-3′, which also
contain adaptors for down-stream Illumina MiSeq sequen-
cing as described previously [9]. Each sample was amplified
with a unique (12 base) barcoded reverse primer.
PCR amplification was undertaken with Q5 High-fidelity
DNA Polymerase (New England BioLabs). Each reaction
mix contained DNA template (1 μl), 5 x Q5 Buffer (5 μl),
10mM dNTPs (0.5 μl), 10 μMF primer (1.25 μl), 10 μM R
primer (1.25 μl), Q5 Taq (0.25 μl) and sterile, deionised
water (15.75 μl) to a final volume of 20 μl. The PCR amplifi-
cation conditions were as follows: 2min at 98 °C; 20 cycles
of 30 s at 98 °C, 30 s at 50 °C, 120 s at 72 °C; ending with 5
mins at 72 °C then a holding temperature at 10 °C. Four
PCR reactions were prepared for each DNA sample as de-
scribed previously [9]. Following confirmation of adequate
and appropriately sized product by gel electrophoresis, the
quadruplicate reactions were pooled and ethanol precipi-
tated and then quantified using a Qubit 2.0 Fluorometer
(Life Technologies Ltd). A sequencing master-mix was cre-
ated using equimolar concentrations of DNA from each
sample. Sequencing was carried out on an Illumina MiSeq
machine, using 2 × 250 bp read length, at the Wellcome
Sanger Institute (Cambridgeshire, UK). Sequence data has
been deposited in the European Nucleotide Archive and is
available under study accession number ERP015431, and
sample accession numbers ERS1138028 to ERS1138179
(Additional file 2: Table S2).
The sequences obtained were analysed using the
Mothur software package [54] with the forward and re-
verse reads assembled into paired read contigs. Any
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paired contigs that were shorter than 270 bp, longer than
480 bp, contained ambiguous bases or contained homo-
polymeric stretches of longer than 7 bases were then
removed. Unique sequences were grouped together and
aligned against the SILVA reference database. Pre-
clustering (diffs = 3) was performed to reduce the impact
of sequencing errors. Rare sequences were removed (cut
off = 5) and the OTUs were generated at a 97% similarity
cut-off level using the default OptiClust setting in mothur.
Reads from chloroplast, mitochondria, archaea, eukaryote
and unknown sequences were removed from the dataset
[55]. As a result, the final dataset had a total of 1,290,544
sequences with a range of 3928–40,532 sequences per
sample. All samples were rarefied to 3928 reads to ensure
equal sequencing depth for all comparisons (average
Good's coverage at this sequence depth was 98%). The
final OTU-level results are shown in Additional file 6:
Table S5 A, B. Metastats analysis [56] was used to deter-
mine any OTUs that were significantly different between
two sample cohorts (washout versus AXOS), and p-values
were corrected as described previously [57] to allow for
the false discovery rate over multiple comparisons. Signifi-
cant associations across all cohorts were identified using
LEfSe analysis [58]. The Shannon diversity index was used
to calculate bacterial diversity per sample.
Short chain fatty acid (SCFA) analysis
SCFA levels in faecal samples were measured by gas chro-
matography as described previously [59]. Following deriva-
tisation of the samples using N- tert-butyldimethylsilyl-N-
methyltrifluoroacetamide, the samples were analysed using
a Hewlett Packard gas chromatograph fitted with a fused
silica capillary column with helium as the carrier gas.
Faecal calprotectin analysis
Faecal calprotectin levels were measured using The CALP
RO Calprotectin ELISA test (ALP) (CALPRO AS,
Norway) following the manufacturer’s instructions. Briefly,
approximately 100mg of faeces was mixed with 4.9 ml di-
luted faecal extraction buffer. Diluted sample extracts and
controls were dispensed into the plate wells coated in
immunoaffinity-purified polyclonal rabbit antibodies spe-
cific for calprotectin and incubated at room temperature
on a horizontal plate shaker for 45 mins at 500–700 rpm.
The wells were washed and 100 μl enzyme substrate solu-
tion added per well, then 100 μl 1M NaOH was added to
stop the reaction. The plates were read at an optical dens-
ity of 405 nm using an ELISA plate reader and values used
to calculate calprotectin concentrations.
Blood glucose, cholesterol, HDL, LDL, triglyceride
measurement
Whole blood was collected in EDTA vacutainers. A
small aliquot was set aside at room temperature for lipid
profile and glucose measurements immediately. Total
cholesterol, high density lipids (HDL) cholesterol, low
density lipids (LDL) cholesterol, non-HDL cholesterol,
triglyceride and glucose were measured using Alere
Cholestech LDX® LIPIS PROFILE GLU cassettes and
analysed using an Alere Cholestech LDX® reader, follow-
ing the manufacturer’s instructions.
Statistical analysis
We aimed for a minimum of twenty subjects since previ-
ous studies have demonstrated that this is a sufficient
sample size for significance for short chain fatty acids
and microbiota analysis [15], and twenty-one volunteers
completed this study. Sequencing and SCFA data from
these experiments were analysed by ANOVA with
donor, time and substrate within donor as random ef-
fects, and with substrate, time and their interaction as
fixed effects. When an effect was significant (P < 0.05)
mean values were then compared by post-hoc t-test
based on the output from the ANOVA analysis. The
Benjamini-Hochberg test [57] was applied to correct for
false discovery rate. For validation purposes, the Wil-
coxon signed-rank test was applied to data that showed
significance using LEfSe and Metastats analysis.
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